Ascentage Pharma Group International, a trailblazer in the biopharmaceutical industry with a worldwide presence, is poised to unveil 17 pivotal clinical advancements at the forthcoming 31st Congress of the European Hematology Association (EHA2026). This esteemed gathering is scheduled to occur in Stockholm, Sweden, from June 11 to 14, 2026, and will feature eight poster presentations that underscore the company's strides in cancer treatment innovations.
The presentations will spotlight data from ongoing research on Olverembatinib (HQP1351), recognized as China's inaugural third-generation BCR-ABL inhibitor, and Lisaftoclax (APG-2575), the first Bcl-2 selective inhibitor developed in China. These breakthroughs are emblematic of Ascentage Pharma's dedication to addressing critical unmet needs in oncology and hematology.
Highlighted Presentations at EHA2026
A notable presentation will delve into the updated efficacy and safety profile of Olverembatinib as a second-line treatment for patients with chronic-phase chronic myeloid leukemia (CP-CML). This study, spearheaded by Dr. Weiming Li from Huazhong University of Science and Technology, is slated for presentation on June 13.
Another pivotal study, led by Dr. Elias Jabbour from The University of Texas MD Anderson Cancer Center, will investigate the effectiveness of Olverembatinib in CP-CML patients who have previously shown resistance to Ponatinib or Asciminib and possess ASXL1 mutations. This research underscores Olverembatinib's potential to surmount resistance in complex cases.
Further presentations will reveal findings from the POLARIS-1 global registrational Phase 3 study, which evaluates Olverembatinib in combination with low-intensity chemotherapy for newly diagnosed Ph+ ALL patients, as well as the correlation of baseline characteristics with prognosis in CLL/SLL patients treated with Lisaftoclax in a pivotal Phase 2 study.
Exploring Innovative Therapies
Olverembatinib and Lisaftoclax are currently under investigation and have not yet secured FDA approval in the United States. Nonetheless, they signify substantial progress in the treatment of hematologic malignancies, with Olverembatinib already approved in China for specific CML cases and Lisaftoclax approved for CLL/SLL treatment.
Ascentage Pharma is advancing its pipeline with multiple global registrational Phase III trials, including the POLARIS-2 trial for CML, POLARIS-1 for Ph+ ALL, and POLARIS-3 for SDH-deficient GIST patients. The company is also conducting the GLORA studies for Lisaftoclax across various hematologic conditions.
Strategic Collaborations and Future Outlook
With formidable research and development capabilities, Ascentage Pharma has cultivated a robust portfolio of intellectual property rights and forged strategic alliances with leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent. These partnerships are designed to expedite the development and commercialization of groundbreaking therapies.
As the company gears up to present its latest discoveries at EHA2026, it remains steadfast in its commitment to advancing cancer treatment and enhancing patient outcomes globally. The upcoming congress will serve as a platform for Ascentage Pharma to disseminate its cutting-edge research to the international hematology community and further its mission to revolutionize cancer care.